COVID-19
Read Time: 2 mins

Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals Hospitalized with SARS-CoV-2

Published Online: July 20th 2022 touchREVIEWS in Infectious Diseases 2022;1(1): Online ahead of journal publication
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Alicia Grima

Alicia Grima is a recent graduate of the Master of Public Health in Epidemiology programme at the University of Toronto, Canada. Throughout her degree she has worked as a researcher with two infectious disease groups. Most recently she has been part of a modelling group within the Dalla Lana School of Public Health, investigating several outcomes of interest relating to the SARS-CoV-2 pandemic. Findings from this research have been published and presented at The European Society of Clinical Microbiology and Infectious Diseases conference. This year, Alicia will be continuing her studies at the University of Toronto, pursing a PhD in Epidemiology.

Keywords

SARS-CoV-2, hospitalization, vaccine, intensive care unit, death, virulence, Ontario

Article:

Q. What were the aims and design of your study?

As novel variants of SARS-CoV-2 emerge, vaccines against the virus may become less effective at preventing infection, as was seen with the B.1.529 (Omicron) variant.1 As such, we sought to investigate whether prior vaccination reduced the risk of severe outcomes. We created a time-matched cohort of individuals hospitalized due to SARS-CoV-2 using data from Ontario, Canada. Matching was based on test date with up to five unvaccinated individuals matched to a single vaccinated individual. Risk of intensive care unit (ICU) admission and risk of death were evaluated using conditional logistic regression. Exploratory analysis also investigated whether the protective effects from vaccination were modified based on patient characteristics or variant.

Q. What did the results tell us about the impact of vaccination on the risks of requiring treatment in intensive care and death?

Compared with no vaccination, vaccination with one, two or three doses significantly reduced the risk of ICU admission and death, conditional on hospitalization. The reduction in risk was found to be greater for ICU admission than for death.

Q. What were the strengths and limitations of this study?

Our study was time matched, which reduces the likelihood that our findings were impacted by changes in circulating variant or vaccine prioritization. Additionally, the restriction to hospitalized individuals in our study reduces potential bias due to differential testing in vaccinated and unvaccinated individuals.

One important limitation of our study, however, is the inability to ensure that the effects observed are not at least in part due to residual confounding. Our study results also lacked statistical power to estimate Omicron-specific protection owing to time lags and the recent emergence of the variant.

Q. What is the take-home message from these findings?

Even when the vaccine fails to prevent infection and subsequent hospitalization due to SARS-CoV-2, the vaccine offers protective effects against severe outcomes. As such, high vaccination rates are extremely important for public health.

Article Information:
Disclosure

Alicia Grima has no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article is an interview and did not involve any studies with human or animal subjects performed by the author.

Review Process

This is an expert interview and, as such, has not undergone the journal’s standard peer-review process.

Authorship

The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.

Correspondence

Alicia Grima, Dalla Lana School of Public Health, University of Toronto, 155 College St Room 500, Toronto, ON M5T 3M7, Canada.
E: alicia.grima@mail.utoronto.ca

Support

SupportNo funding was received in the publication of this article.

Access

This article is freely accessible at touchINFECTIOUSDISEASES.com

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this article.

Received

2022-05-20

References

  1. Hogan AB, Wu SL, Doohan P, et al. Report 48 – The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant. Available at: imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-48-global-omicron/(accessed 17 December 2021).

Further Resources

Share this Article
Related Content In COVID-19
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72